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re are honored to again provide readers of the Journal with
comprehensive review of major scientific works related to
nterventional cardiology published in 2004. Since our
riginal 2003 review, the field of interventional cardiology
as continued to expand rapidly. Although this field origi-
ally encompassed coronary interventions, we have been
sked to include other cardiac (nonvalvular) interventions
nd peripheral artery interventions. Our goal is not to
rovide the reader with an exhaustive list of references;
ather, we wish to organize all major practice-changing
tudies and major randomized trials into themes. We believe
hat noninterventional cardiologists can achieve a thorough
pdate and that interventionists will be provided with a
ramework for more intensive study. We have reviewed over
00 papers and selected 100 for inclusion. Although we
ay have some biases in selection, we believe that these
orks will move this field forward (Table 1). We hope you
njoy reading about them as much as we enjoyed organizing
hem for you.
CUTE MYOCARDIAL INFARCTION (AMI)
he American College of Cardiology/American Heart As-
ociation (ACC/AHA) guidelines for the treatment of AMI
ere updated in 2004 (1). Although catheter-based reper-
usion is now widely accepted as the treatment of choice for
T-segment elevation myocardial infarction (STEMI),
any unanswered questions and challenges remain in this
eld. Key issues and areas of research have included: 1)
efining the optimal treatment approach after thrombolysis;
) evaluating the role of facilitated percutaneous coronary
ntervention (PCI) to improve clinical outcomes; and 3)
dentifying new adjunctive therapies to improve myocardial
alvage. In addition, there is now tremendous interest in
tem-cell therapy to repair infarcted myocardium.
CI after thrombolysis (rescue and immediate). Two
rials of rescue angioplasty after failed thrombolytic therapy
ere reported this year (Table 2). The Middlesbrough Early
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omized 307 patients treated with streptokinase, who had a
ack of ST-segment resolution, to transfer for catheterization
ersus medical therapy (2). The secondary end point of major
dverse cardiac events (MACE) was reduced in the rescue PCI
rm (37.3% vs. 50.0%, p  0.02) due to a reduction in
schemia-driven revascularization. However, stroke and trans-
usions were more common in the rescue group, and there was
o difference in mortality. An accompanying editorial pointed
ut several reasons why the results of the MERLIN trial
onflicted with other studies (3). The larger Rescue Angio-
lasty Versus Conservative Therapy or Repeat Thrombolysis
rial (REACT) was presented at the 2004 AHA meeting (4).
atients with a lack of ST-segment resolution 90 min after
hrombolysis (n 427) were randomized to three arms: rescue
CI, repeat thrombolysis using tissue-type plasminogen acti-
ator (tPA) or recombinant plasminogen activator (rPA), or
onservative care. The primary end point of combined death,
e-infarction, stroke, or severe heart failure was significantly
educed in the rescue PCI arm (15.3%) compared with the
epeat lysis arm (31.0%) and with conservative care (29.8%,
 0.001). This benefit was due to a reduction in death,
e-infarction, and heart failure. Moreover, significantly less
schemia-driven revascularization was required in the rescue
CI arm. Recent data from the Stent or Percutaneous Trans-
uminal Coronary Angioplasty for Occluded Coronary Arteries
n Patients With Acute Myocardial Infarction (STOPAMI)
nvestigators indicate that stenting after failed thrombolysis is
ssociated with greater myocardial salvage than balloon angio-
lasty alone (5). In aggregate, these studies suggest that
atients with failed thrombolysis should undergo rescue
tenting.
Previous clinical guidelines discouraged routine angio-
lasty after thrombolysis because of historical (but outdated)
tudies suggesting an excess risk of complications in these
atients. Since then, significant advances in mechanical and
harmacologic therapy have occurred. In the Combined
ngioplasty and Pharmacological Intervention versus
hrombolytics Alone in Acute Myocardial Infarction
CAPITAL AMI) study, tenecteplase (TNK) plus imme-
iate angioplasty was found to be superior to tenecteplase
lone (6) in 170 high-risk STEMI patients. Also, MACE
as significantly reduced at 30 days (9.3% vs. 22.0%, p 
.03) and six months in the TNK-PCI group, due to
eductions in recurrent unstable ischemia and re-infarction.
here was no increase in the incidence of major bleeding. In
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Year in Interventional Cardiology April 5, 2005:1117–34he GRACIA-1 trial, 500 patients treated with tPA were
andomized to an early invasive strategy (stenting within
4 h) or to a conservative (ischemia-guided) approach (7).
he invasive group had a reduction in in-hospital ischemia-
riven revascularization (2% vs. 12%, p  0.0001) and a
horter hospital stay (7.1% vs. 10.5%, p  0.0001), with no
ncrease in bleeding. At one year, the combined end point of
eath, re-infarction, or ischemia-driven revascularization
able 1. Glossary of Interventional Cardiology Trials 2004
Acronym
GENT-3 A multicenter, prospective, randomized trial
revascularization options
IMI AngioJet in Acute Myocardial Infarction
MIHOT Acute Myocardial Infarction with Hyperoxem
RCHER Acculink for revascularization of carotids in h
RTS-II A multicenter, prospective, registry of multiv
OOST BOne marrOw transfer to enhance ST-elevat
RAVE Bavarian Reperfusion Alternatives Evaluation
RIDGE Beta-Radiation Investigation With Direct St
ABERNET A prospective registry of carotid stenting with
patients
APITAL AMI Combined Angioplasty and Pharmacological
APTIVE A prospective, randomized, controlled trial o
to the GuardWire of FilterWire
ARP Coronary Artery Revascularization Prophylax
ASTEMI Caldaret in ST-Elevation Myocardial Infarct
REATE-ECLA Clinical Trial of Metabolic Modulation in A
Latinoamérica
REAM Dutch Randomized Endovascular Aneurysm
ASTER Estrogen and Stents To Eliminate Restenosi
MERALD Enhanced Myocardial Efficacy and Removal
UTURE First Use to Underscore restenosis Reduction
RACIA-1 Grupo de Análisis de la Cardiopatia Isquémi
CE-IT Intravascular Cooling adjunctivE to percutan
SAR-DESIRE Intracoronary Stenting and Antithrombotic R
SAR-REACT Intracoronary Stenting and Antithrombotic R
SAR-SWEET Intracoronary Stenting and Antithrombotic R
Risk in Diabetics
AGIC Cell A randomized trial of intracoronary infusion
factor on left ventricular systolic function a
AVERICK II A prospective registry of carotid stenting with
patients
ERLIN Middlesbrough Early Revascularization to Li
n-TIME Ongoing Tirofiban in Myocardial Infarction
RBIT Oral Rapamune to Inhibit Restenosis
SIRIS Oral Sirolimus to Inhibit Recurrent In-stent
OZNAN Percutaneous transvenous transplantation of a
RIDE A prospective, randomized, controlled trial o
GuardWire or FilterWire
ROVE-IT Pravastatin or Atorvastatin Evaluation and In
EACT REscue Angioplasty versus Conservative ther
ESCUT Restenosis Cutting Balloon Evaluation Trial
ESEARCH Rapamycin-Eluting Stent Evaluated At Rott
EPLACE Randomized Evaluation in PCI Linking Ang
APPHIRE Stenting and Angioplasty with Protection in
ES-SMART A randomized comparison of a sirolimus-elut
coronary arteries
PIRIT FIRST A randomized trial of the MultiLink Vision
YMBIOT A prospective, randomized trial of a PTFE s
YNERGY Superior Yield of the New Strategy of Enoxa
AXUS VI A prospective registry of late outcomes with
OPCARE Transplantation of Progenitor Cells and Regas lower in the invasive group (9% vs. 21%, p  0.0008). oaken together, these studies indicate that in the era of
tents and newer antiplatelet agents, routine PCI after
hrombolysis is not only safe but also improves outcomes
nd thus may be preferable to “watchful waiting.”
acilitated PCI. Prognosis is favorable in AMI patients
eferred for primary PCI who are found to have Thrombolysis
n Myocardial Infarction (TIMI) flow grade 3 on baseline
ngiography, compared with TIMI flow grade 0 to 2. Based
Trial
racoronary administration of Ad5FGF-4 in patients with no
erapy
isk patients
tenting with the polymer-based sirolimus-eluting stent
farct regeneration
and Galileo in Europe
Nexstent and distal protection with the FilterWire EX in high-risk
vention versus Thrombolytics Alone in Acute Myocardial Infarction
l protection with the third-generation MedNova EmboShield compared
yocardial Infarction Treatment Evaluation-Estudios Cardiológicos
gement
piration of Liberated Debris
Everolimus
uda
oronary InTervention
en—Drug-Eluting Stents For In-stent Restenosis
en—Rapid Early Action for Coronary Treatment
en—Is Abciximab a Superior Way to Eliminate Elevated Thrombotic
ripheral blood stem-cells mobilized with granuloyte-colony stimulating
stenosis
Exponent stent and distal protection with the GuardWire in high-risk
farction
ation
sis
gous myoblasts in the treatment of post-infarction heart failure
l protection with the Kensey-Nash TriActiv system compared to the
n Therapy—Thrombolysis in Myocardial Infarction 22
r repeat Thrombolysis
Cardiology Hospital
x to Reduced Clinical Events
nts at High Risk for Endarterectomy
tent and a standard stent in the prevention of restenosis in small
limus-eluting stent
panding stent graft during SVG intervention
, Revascularization, and Glycoprotein IIb/IIIa Inhibitors
oderate rate-release paclitaxel-eluting stent in long lesions
ion Enhancement in Acute Myocardial Infarctionof int
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April 5, 2005:1117–34 Year in Interventional Cardiologyharmacologically facilitate reperfusion before primary PCI.
he Bavarian Reperfusion Alternatives Evaluation (BRAVE)
rial randomized 253 patients with STEMI to facilitated PCI
ith half-dose reteplase plus abciximab, versus abciximab alone
8). Despite the delay in PCI (74% of patients had to be
ransferred), infarct size measured by technetium (Tc)-
estamibi was similar between the two groups. Major bleeding
ended to be higher in the facilitated group (5.6% vs. 1.6%, p
0.16), and MACE at six months was similar. The Ongoing
irofiban in Myocardial Infarction Evaluation (ON-TIME)
rial randomized 507 patients with STEMI who required
ransfer for PCI to receive prehospital tirofiban (facilitated)
ersus primary PCI (9). There was no difference in post-PCI
erfusion, as assessed by final TIMI flow grade, blush score, or
orrected TIMI frame counts. Moreover, there was a trend
able 2. Interventional Trials in Acute Myocardial Infarction in
Study Design n
CI after thrombolysis
BRAVE (8) AMI 12 h; randomized to
pretreatment with abciximab alone
or half-dose reteplase  abciximab
253
CAPITAL AMI* (6) AMI 6 h; randomized to
thrombolysis alone (TNK) or
TNK  immediate PCI
170
MERLIN (2) AMI 10 h; patients with 50%
STR 90 min after thrombolysis;
randomized to emergency
angiography with or without
rescue PCI or conservative therapy
307
REACT (4) AMI; patients with 50% STR 90
min after thrombolysis;
randomized to conservative (IV
heparin), repeat lysis, or rescue
PCI
427
djunctive therapies and
devices to enhance
myocardial salvage
AIMI* (22) AMI 12 h; randomized to
thrombectomy (AngioJet) and
stent vs. stent alone
480
AMIHOT* (24) AMI 24 h; randomized after
primary PCI to intracoronary
hyperoxemic reperfusion with
aqueous oxygen (AO) or control
269
CASTEMI* (25) AMI 6 h; randomized to placebo,
57.5 mg caldaret or 172.5 mg
caldaret
387
EMERALD* (23) AMI 6 h; randomized to PCI with
distal protection using the
GuardWire device or PCI alone
501
ICE-IT* (27) AMI 6 h; randomized to PCI with
mild hypothermia or PCI alone
228
Trial presented at scientific meetings but not yet published.
AMI acute myocardial infarction; MACE major adverse cardiac events; PCI
esolution.oward increased MACE in the facilitated group at 30 days t8.6% vs. 4.4%, p  0.06). Thus, to date, no trial has shown
hat facilitated PCI is superior to primary PCI alone.
rimary PCI. The Primary Angioplasty in Myocardial
nfarction (PAMI)–No cardiac Surgery On-Site (No SOS)
egistry prospectively enrolled and performed primary PCI
n 500 consecutive, high-risk, thrombolytic-eligible AMI
atients who presented to hospitals with No SOS (10). No
OS patients were compared with similar high-risk patients
ho were randomized to transfer for primary PCI. Patients
ho received primary PCI with no SOS were treated 67
in earlier and had a higher rate of final TIMI flow grade
(96% vs. 86%, p  0.004) and trend toward improved
ACE.
Management of the thrombolytic-ineligible patient re-
ains uncertain. The STOPAMI-3 trial randomized 611
Primary Study End Point Principal Results
farct size by SPECT imaging Higher incidence of initial TIMI flow
grade 3 in reteplase  abciximab
group, but no difference in final
infarct size (13% vs. 11.5%, p 
NS)
eath, MI, recurrent angina,
stroke at 30 days
Significant reduction in primary end
point in the TNK  PCI group
(9.3% vs. 22.0%); no difference in
bleeding between groups
ll-cause mortality at 30 days Mortality similar in study groups; less
revascularization in the rescue
group (6.5% vs. 20.1%, p  0.01)
omposite of death, nonfatal
MI, stroke, or significant
heart failure
Significant reduction in primary end
point in rescue PCI group (15.3%)
compared with conservative therapy
(29.8%) or repeat lysis (31.0%)
farct size by SPECT imaging
at 14 to 28 days
No reduction in infarct size with
rheolytic thrombectomy; higher
mortality in thrombectomy group.
WM of infarct zone at 3
months; ST-segment
resolution; infarct size at 14
days
No difference in study end points
with AO, but trend toward
improved RWM in overall group
In patients 6 h, reduced infarct size
and improved RWM
farct size at 7 days Overall, no difference in infarct size
farct size by SPECT imaging
at 5 to 14 days; ST-segment
resolution 30 min after PCI
No difference in infarct size or ST-
segment resolution with
GuardWire
farct size by SPECT imaging Overall, no difference in primary end
point, but reduction of infarct size
in anterior MI group
utaneous coronary intervention; RWM regional wall motion; STR ST-segment2004
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Year in Interventional Cardiology April 5, 2005:1117–34ransluminal coronary angioplasty (PTCA) (11). Patients
ere immediately injected with Tc-sestamibi and scanned
o determine the initial perfusion defect size, and follow-up
cintigraphy was performed at 7 to 14 days. The salvage
ndex was substantial in both the stent and PTCA groups
0.54 and 0.50, p  0.20), suggesting that either primary
CI strategy would greatly benefit thrombolytic-ineligible
atients.
Some have questioned whether performance of primary
CI during “off-hours” is harmful to AMI patients. In the
ontrolled Abciximab and Device Investigation to Lower
ate Angioplasty Complications (CADILLAC) trial of
,082 patients undergoing primary PCI, 49% of patients
resented during the evening or weekend (12). Although
ime-to-treatment was delayed an additional 21 min, this
id not influence procedural success, myocardial recovery, or
urvival after PCI.
In pooled PAMI trials of 3,065 patients undergoing
rimary PCI, sustained ventricular tachycardia (VT) or
entricular fibrillation (VF) in the catheterization laboratory
as noted in 4.3% (13). Independent predictors of VT/VF
ncluded smoking, shorter time-to-treatment, initial TIMI
ow grade 0, right coronary infarct vessel, and lack of
reprocedural beta-blockers. Although the initial catheter-
zation laboratory course was more complicated, the in-
ospital and one-year adverse events were similar to those in
atients without these arrhythmias.
Predicting the risk of patients undergoing primary PCI
as the subject of multiple publications. The PAMI risk
core found that preprocedural clinical criteria were useful
14), but PCI success was a more important determinant
15). The CADILLAC study group found that death,
ajor bleeding, and stroke rates continued to be high in
lderly patients undergoing primary PCI, and that these
utcomes were not affected by stents or glycoprotein IIb/
IIa receptor inhibitors (16). Additional risk factors of poor
utcome after primary PCI included baseline anemia (17),
ny degree of mitral regurgitation (18), lack of myocardial
lush (19), or ST-segment resolution (20). Early re-
cclusion after primary PCI occurred more frequently in
essels that were aneurysmal, involved bifurcations, were
reated with smaller balloons, and did not received abcix-
mab (21).
herapies and devices to enhance myocardial salvage.
ix clinical trials evaluating new adjuncts to mechanical
eperfusion were reported in 2004 (Table 2). Two of these
rials (AngioJet in Acute Myocardial Infarction [AIMI] and
nhanced Myocardial Efficacy and Removal by Aspiration
f Liberated Debris [EMERALD]) investigated methods
o reduce distal embolization, whereas the other four ex-
lored adjunctive therapies to limit reperfusion injury
Acute Myocardial Infarction With Hyperoxemic Therapy
AMIHOT], Calderet in ST-Elevation Myocardial Infarc-
ion [CASTEMI], Clinical Trial of Metabolic Modulation
n Acute Myocardial Infarction Treatment Evaluation-
studios Cardiológicos Latinoamérica [CREATE- tCLA], and Intravascular Cooling Adjunctive to Primary
oronary Intervention [ICE-IT]).
In the AIMI and EMERALD trials, it was hypothesized
hat use of the AngioJet (Possis Medical Inc., Minneapolis,
innesota) or GuardWire (Medtronic, Santa Rosa, Cali-
ornia) devices, respectively, would prevent distal emboliza-
ion, improve microcirculatory flow, and thus reduce final
nfarct size (22,23). In the AIMI trial, patients were
andomized to primary PCI with or without rheolytic
hrombectomy using the AngioJet device before stent im-
lantation (22). Surprisingly, the primary end point (infarct
ize by single-photon emission computed tomographic
SPECT] imaging) was higher in the thrombectomy group
12.1% vs. 10.9%, p  0.02), and there was no difference in
nal TIMI flow grade, myocardial blush, TIMI frame
ount, or ST-segment resolution between the study groups.
oreover, there was a significantly higher incidence of
ACE at 30 days in the thrombectomy arm (6.7% vs.
.7%, p  0.01). In the EMERALD trial, the GuardWire
alloon occlusion and aspiration system (Medtronic) was
sed for embolic protection during the angioplasty proce-
ure (23). Although visible debris was retrieved in 70% of
ases treated with the protection device, this was not
ssociated with any improvement in final TIMI flow grade,
yocardial perfusion, infarct size, or clinical events. Taken
ogether, these data do not support the routine use of either
he AngioJet or GuardWire during mechanical reperfusion.
hether these devices are useful in patients with a large
hrombus burden needs further investigation.
The AMIHOT trial investigated the use of hyperoxemic
eperfusion with Aqueous Oxygen (AO) during AMI (24).
fter stent implantation, patients in the AO group received
90-min intracoronary infusion of blood supersaturated
ith oxygen. One important difference in study design,
ompared with previous reperfusion trials, was that patients
ere eligible for enrollment up to 24 h from symptom onset.
yperoxemic reperfusion was safe and well tolerated; how-
ver, there was no significant improvement in the primary
tudy end points (ST-segment resolution, regional wall
otion by serial echocardiography, and SPECT infarct
ize). In a secondary analysis, there did appear to be a
reatment benefit in patients presenting within 6 h, and a
urther trial is being planned to confirm these observations.
In the CASTEMI trial, 387 AMI patients were treated
ith intravenous caldaret (an agent that reduces intracellular
alcium levels by inhibiting the Na/Ca exchanger and
ncreasing uptake into the sarcoplasmic reticulum) (25). In
he treatment arm, two doses of caldaret were studied (low
ose of 57.5 mg and high dose of 172.5 mg). There was no
ifference in the primary end point (infarct size at day 7)
etween the study groups; however, a benefit was seen in
nterior myocardial infarction (MI) patients in the high-
ose group. A larger clinical trial with caldaret (EVOLVE)
s currently in progress in the U.S.
The results of the recently presented CREATE-ECLA
rial have now settled the question of whether glucose-
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April 5, 2005:1117–34 Year in Interventional Cardiologynsulin-potassium (GIK) improves mortality in AMI pa-
ients (26). In this trial (the largest study of GIK therapy),
0,201 patients with STEMI presenting within 12 h from
ymptom onset were randomized to receive high-dose GIK
nfusion for 24 h or usual care. Approximately 1,800
atients in the trial were treated with primary PCI. At 30
ays, there was no difference in all-cause mortality (control
.7% vs. GIK 10.0%, p  0.45) or any secondary outcome
easures, including cardiac arrest, cardiogenic shock, or
e-infarction.
Finally, results of the ICE-IT study, the second trial to
nvestigate hypothermia during AMI, were also reported
his year (27). Patients randomized to receive hypothermia
ere cooled with an endovascular cooling catheter for 6 h
Innercool Inc., San Diego, California). The trial was
iscontinued after 228 patients were enrolled. There was no
ifference in final infarct size (the primary end point) in the
ypothermia group. In post-hoc analysis, anterior MI pa-
ients who received sufficient cooling before reperfusion
ppeared to have a reduction in infarct size—an observation
oncordant with the previously reported Cooling as an
djunctive Therapy to Percutaneous Intervention in Pa-
ients With Acute Myocardial Infarction (COOL MI) trial.
ell-based cardiac repair. Cell therapy for myocardial
egeneration has received enormous attention due to the
otential for stem cells to potentially differentiate into
ultiple cell types, as well as the ready availability of
utologous cells (using the patient’s own bone marrow-
erived stem cells or skeletal myoblasts).
Skeletal muscle contains precursor cells (satellite cells/
yoblasts), which are able to divide and repopulate the
yocardium. At the ACC meeting in March 2004, Siminiak
28) reported a new method of myoblast transplantation via
catheter in the cardiac vein, which allows transvenous
eedle puncture of the myocardium. In a series of 10
atients, the injections were successfully delivered in nine,
nd one patient was noted to develop VT. Dib et al. (29)
eported myoblast transplant during coronary artery bypass
raft surgery (CABG) in 22 patients. Subsequent positron
mission tomography (PET) scanning confirmed improved
iability. Four patients were noted to have VT in this series.
rrhythmias have been a persistent concern in clinical trials
f myoblast transplantation and have resulted in trials being
topped and/or modified to require automatic implantable
ardioverter-defibrillator (AICD). The increase in arrhyth-
ias is thought to be due to needle injections (puncture sites
howing disordered growth, delayed differentiation, and
urrounded by fibrous tissue), as well as failure to form
lectromechanical coupling with native myocytes. Injection
f myoblasts rather than stem cells (which can potentially
ifferentiate into myocardium, capillaries, as well as the
onduction system) may also predispose to arrhythmias.
Use of stem cells for myocardial regeneration has been the
ubject of multiple recent investigations. The Bone Marrow
ransfer to Enhance ST-Elevation Infarct RegenerationBOOST) trial randomized 60 patients to control (n  30) sr intracoronary bone marrow-derived cell (BMC) infusion
.8 days after PCI (n  30) (30). At six months, the global
jection fraction increased only 0.7% in the control group
nd 6.7% in the BMC group (p  0.003). No proarrhyth-
ic events or increase in restenosis were noted. Although
hese results are promising, it is important to point out that
aseline ejection fraction was high (51.3% in the control
roup), and the benefit of cell transplantation was magnified
ue to the unexpected lack of improvement in the control
roup. Furthermore, this was a very heterogeneous popula-
ion, with 40% of patients receiving thrombolytic therapy,
nd PCI was performed between 2 and 120 h from
ymptom onset. This suggests that spontaneous improve-
ent may have occurred (and would be expected) in some
atients. Alternatively, the TECAM pilot study (31) en-
olled 20 patients with a large MI and no viability by
ow-dose dobutamine echocardiography, all of whom re-
eived intracoronary infusion of bone marrow-derived stem
ells. At magnetic resonance imaging (MRI) follow-up,
mproved wall thickness, wall motion, and ejection fraction
ere noted in the BMC group, which appeared to be
uperior to the results in a nonrandomized control group.
onversely, Kuethe et al. (32) treated five patients with a
arge anterior MI with intracoronary BMC and found no
mprovement at three months in ejection fraction, regional
all motion, contractility index, coronary flow reserve, or
aximum oxygen uptake. The authors suggest the “eupho-
ia” created by small studies may be premature.
Use of circulating stem cells provides an attractive alter-
ative to performing multiple bone marrow aspirates. The
OPCARE-AMI trial (33) reported one-year follow-up in
9 patients randomized to receive intracoronary circulating
tem cells versus bone marrow cells 4.9 days after AMI. No
ate deaths or arrhythmias were noted, and both groups had
imilar improvements in ejection fraction and a reduction in
nfarct size. These data suggest that circulating stem cells
re as safe and effective as BMCs. However, stem cells
irculate in the peripheral blood in very low numbers.
ranulocyte colony-stimulating factor (GCSF) has been
sed clinically in patients with immunosuppression or pan-
ytopenia and to harvest cells for bone marrow transplan-
ation. The GCSF has recently been used in AMI patients
o mobilize stem cells into peripheral blood, both for
arvesting cells for intracoronary infusion and in studies
tilizing GCSF alone. The latter technique assumes signal-
ng factors released during myonecrosis promote homing,
ngraftment, and differentiation of passively circulating
tem cells in the myocardium. However, induction of
eukocytosis shortly after AMI is controversial. Numerous
tudies have shown that even a slight elevation in leukocytes
s associated with worse outcomes. Some animal studies
ave suggested greater infarct expansion and mortality (34).
o date, six small clinical studies have been reported and
emonstrate mixed results (Table 3). The largest of these
mall series are MAGIC Cell and FIRSTLINE-AMI.
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Year in Interventional Cardiology April 5, 2005:1117–34The MAGIC Cell trial (35) randomized 27 patients with
MI to usual care, GCSF alone, or GCSF followed by
pheresis to harvest the cells followed by intracoronary
nfusion. PCI was performed four days after randomization,
nd follow-up angiography in 10 patients demonstrated a
0% restenosis rate. Because peak GCSF-induced leukocy-
osis occurs at day 4, performing PCI in this milieu may
ave contributed to high restenosis rates. Alternatively, the
IRSTLINE-AMI trial enrolled 30 patients with a large
I and successful PCI to control versus GCSF (starting
fter PCI) (36). With this approach, restenosis occurred in
nly 13%, and GCSF-treated patients were noted to have
etter ejection fraction and left ventricular volumes.
In aggregate, these pilot studies are promising but have
ot shown improvement in clinical outcome. Once cell type
nd delivery technique are optimized, pivotal multicenter,
ontrolled trials in high-risk patients must be performed.
actors influencing clinical outcomes after primary
CI. PERIPROCEDURAL BETA-BLOCKADE. Two studies
eported this year emphasized the prognostic importance of
eta-blocker therapy in patients treated with mechanical
eperfusion (37,38). In a report from the CADILLAC trial,
alkin et al. (37) found that administration of intravenous
eta-blockers before primary PCI was associated with im-
roved 30-day survival and myocardial recovery at seven
onths. Kernis et al. (38) analyzed outcomes in 2,442
able 3. Clinical Trials of Stem-Cell Therapy After Acute Myoc
Study Design n Cel
OOST (30) Primary PCI for AMI;
randomized to BMSC or
control
60 BMSC
IRSTLINE (36) Primary PCI for AMI;
randomized to G-CSF
vs. control
30 Bone marro
with G-C
AGIC Cell (35) Primary PCI for AMI;
randomized to 3 groups:
cell infusion, G-CSF
alone, or control
27 PBSC after
mobiliza
OZNAN (28) Phase I trial of percutaneous
delivery of autologous
skeletal myoblasts
10 Autologous
OPCARE (33) Primary PCI for AMI;
randomized to BMSC or
PBSC
59 BMSC and
MI  acute myocardial infarction; BMSC  bone marrow stem cell; EF  ejection
ell; PCI  percutaneous coronary intervention.atients from the PAMI trials and found that patients ieceiving oral beta-blockers after successful primary PCI
ad a threefold lower incidence of death at six months. The
reatest benefit of beta-blocker therapy was seen in patients
ith multivessel disease or a low ejection fraction.
IME TO TREATMENT ISSUES. As we previously stated,
004 was the year when infarct angioplasty left the realm of
linical research and became mainstay therapy for STEMI.
he ACC/AHA STEMI guidelines have attempted to
lace primary PCI into the context of community practice
1). Many of these updated recommendations involve issues
uch as access to mechanical reperfusion and time delays
nherent in this approach. The STEMI Committee was
reatly influenced by the report from Nallamothu et al. (39),
hich suggested little benefit for primary PCI if the delay
or door-to-balloon time versus door-to-needle time was
60 min. Therefore, the Committee promoted a 90-min
oor-to-balloon time as an optimal target. However, older and
icker patients have longer delays. In a pooled analysis of all the
andomized trials of thrombolysis versus PCI, thrombolysis
as never superior to PCI, regardless of the time delay (40). De
uca et al. (41,42) reviewed the Zwolle experience from
997 to 2001. They found that a delay to treatment
ignificantly impacted ST-segment resolution, myocardial
lush grade, and one-year survival. Data regarding off-hours
CI remain conflicting. It is clear that door-to-balloon time
l Infarction
e Delivery Results
Intracoronary infusion At 6 months, improved EF in
bone marrow cell group
(6.7% change vs. 0.7%
change in controls, p 
0.0026); no difference in
risk of restenosis,
arrhythmia, or adverse
clinical events
mulation Passive from circulation Improved EF and LV volume
with G-CSF. Restenosis in
only 13%
SF Intracoronary infusion Improved myocardial
perfusion, EF, and exercise
capacity in patients who
received cell infusion, but
high rate of in-stent
restenosis in patients who
received G-CSF
blasts Intramyocardial injection
from cardiac veins
Percutaneous cell delivery safe
and feasible
C Intracoronary infusion Stem cell infusion safe and
feasible; compared with
historical controls, patients
treated with cell infusion
had improved EF and
regional wall motion in
infarct zone
n; G-CSF  granulocyte colony–stimulating factor; PBSC  peripheral blood stemardia
l Typ
w sti
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G-C
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PBSs prolonged off-hours. Sadeghi et al. (12) reported that no
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April 5, 2005:1117–34 Year in Interventional Cardiologyeleterious effect occurred during off-hours PCI in the
,082 CADILLAC patients. Conversely, Saleem et al. (43)
ound in a single-center experience that mortality was
igher (5.8% vs. 3.2%, p  0.05) for 1,050 patients treated
rom 1998 to 2002. Furthermore, Bradley et al. (44) found
hat disparities in time to treatment in racial subgroups
elated more to type of hospital rather than racial bias in
reatment. In summary, the year 2004 started the important
rocess of how practical issues such as catheterization
aboratory volume, staff availability, and treatment delay
ight impact on the routine use of PCI for STEMI in the
ommunity.
CUTE CORONARY SYNDROMES (ACS)
o determine the benefit of routine invasive procedures in
atients who present with ACS, a meta-analysis was per-
ormed of five trials, which randomized 6,766 patients in
he era of stents and glycoprotein IIb/IIIa antagonists (45).
he invasive strategy was superior to conservative care, with
significant reduction in the composite end point of death
r MI at all periods of follow-up, as well as a reduction in
ortality at 24 months (relative risk 0.77, 95% confidence
nterval [CI] 0.60 to 0.99). The greatest benefit was seen in
en and troponin-positive patients. Moreover, the meta-
nalysis would have lended even greater support to the
nvasive approach if it had included the ISAR COOL study
46).
Conversely, the more recent Invasive Versus Conservative
reatment in Unstable Coronary Syndromes (ICTUS) trial
47) randomized 1,200 patients with ACS to an early versus
selective invasive” approach and found no difference in the
omposite end point of death, MI, or re-hospitalization for
CS at one year. The lack of benefit was thought to be
argely due to the aggressive approach in the selective
nvasive group, with 67% receiving catheterization (mean
42 h) and 47% undergoing revascularization. The routine
nvasive strategy did reduce re-admission (7.0% vs. 10.9%,
 0.017), but this was offset by a higher rate of
eriprocedural MI.
Earlier studies of ACS demonstrated that enoxaparin was
uperior to unfractionated heparin (UFH) at reducing com-
ined death and MI; however, its use in combination with
lycoprotein IIb/IIIa agents or invasive procedures was
nknown. Phase A of the Aggrastat to Zocor (A to Z) trial
nrolled 3,987 patients who were receiving tirofiban and
spirin and randomized them to enoxaparin versus UHF
48). A nonsignificant improvement in MACE was ob-
erved in the enoxaparin group (8.4% vs. 9.4%). The
uperior Yield of the New Strategy of Enoxaparin, Revas-
ularization, and Glycoprotein IIb/IIIa Inhibitors (SYN-
RGY) trial enrolled 10,027 patients with high-risk ACS
xpected to undergo early invasive therapy and randomized
hem to enoxaparin versus UFH (49). Overall, death or MI
t 30 days was similar in the enoxaparin and UFH groups
14.0% vs. 14.5%), but a significant increase in bleeding was
C
mbserved with enoxaparin. Increased bleeding was confined
o patients who crossed over and received both treatments;
atients who received only enoxaparin had good clinical
utcomes with minimal bleeding.
CI FOR CHRONIC CORONARY ARTERY DISEASE
CI versus medical therapy or CABG. In the 1990s, 11
andomized trials of PCI versus CABG were completed. In
ggregate, these trials demonstrated that patients treated
ith PCI had a shorter length of stay and less in-hospital
osts. Conversely, CABG-treated patients had better relief
f angina and fewer repeat revascularization procedures. In
004, a number of studies tried to shed further light on the
elative benefits of these two revascularization options.
egrand et al. (50) published the three-year follow-up of the
rterial Revascularization Therapy Study (ARTS). They
howed that mortality was similar in both groups, but repeat
evascularization rates were higher in PCI patients com-
ared with CABG patients (26.7% vs. 6.6%). This advan-
age of CABG may be lessened in the drug-eluting stent
DES) era. Serruys (51) recently presented the six-month
utcome for the ARTS-II trial. In this trial, 600 patients
ere treated in a registry with the Cypher (Johnson and
ohnson, Cordis Corp., Warren, New Jersey) sirolimus
ES, and these patients were compared with the original
tent cohort in the ARTS-I trial, as well as the CABG
ohort in the ARTS-II trial (Table 4). Although this type of
etrospective comparison is not conclusive, it lends support
or the conduct of two prospective CABG versus DES trials
Syntax and Freedom).
Although CABG provides superior anginal relief, a
otential major drawback in quality of life exists. Neuro-
ognitive dysfunction is now recognized as a major risk of
ABG. This year, Wahrborg et al. (52) first reported a
ubstudy of the Surgery or Stent (SoS) trial in which
europsychological outcomes were evaluated. A total of 145
atients were randomized to CABG or PCI. A very low
ncidence of neurologic dysfunction occurred in both
roups, and no differences were detected between the
roups. The large difference in the incidence of neurocog-
itive dysfunction between this study and the Duke study
53) suggests that testing methodology needs to be stan-
ardized. Hopefully, the Syntax or Freedom trial will
xplore this area further.
able 4. Clinical Outcomes in the ARTS-I and ARTS-II Trials
ARTS-I
PCI
ARTS-I
CABG
ARTS-II
DES
eath (%) 2.3 1.8 0.5
yocardial infarction (%) 4.5 3.8 0.7
epeat PCI (%) 7.8 2.0 3.1
epeat CABG (%) 3.8 0.5 1.6
troke (%) 1.5 1.2 0.5
ACE (%) 20.0 9.0 6.4ABG coronary artery bypass graft surgery; DES drug-eluting stent; MACE
ajor adverse cardiac events; PCI  percutaneous coronary intervention.
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Year in Interventional Cardiology April 5, 2005:1117–34Although medical therapy is often forgotten or ignored in
atients eligible for revascularization, interest in alternatives to
evascularization has re-emerged in 2004. Medical therapy
ppears particularly attractive in younger patients with mild
ngina and well-preserved systolic function. Hambrecht et al.
54) randomized 101 such individuals to PCI or medical
herapy. They found that patients assigned to medical
herapy and regular exercise had superior event-free survival
88% vs. 70%, p  0.023) and greater exercise capacity than
hose assigned to PCI. Hueb et al. (55) reported the results
f the Medicine, Angioplasty, or Surgery Study (MASS-II).
n this trial, 611 patients with multivessel disease, 79% of
hom had Canadian Cardiovascular Society (CCS) class II
r III angina, were assigned to medical therapy (n  203),
CI (n  205), or CABG (n  203). At one-year, a trend
oward higher mortality (4.5% vs. 4.0% vs. 1.5%) was
bserved for angioplasty or surgery versus medical therapy.
vent-free survival was greater for CABG (94%) compared
ith medicine (89%) or PCI (76%). Persistent class II or III
ngina occurred in 64% medicine, 45% PCI, and 39%
ABG patients (p 0.001). These two studies suggest that
ntensive medical therapy is safe in younger patients with
table angina. The same may not be true in elderly patients.
fisterer (56) reported the long-term outcome of the Trial
f Invasive vs. Medical Therapy in Elderly Patients With
hronic Coronary Artery Disease (TIME) trial, which
ompared invasive versus medical therapy in the elderly. In
his trial, 301 patients 75 years old were randomized to
evascularization (CABG or PCI) or optimized medical
herapy (47% of patients had CCS angina class III and 35%
ad CCS angina class IV). On an intention-to-treat basis,
o difference in four-year survival was seen between the
roups. This analysis was confounded because 45% of
edically treated patients had late revascularization. Mor-
ality was higher at four years in patients not revascularized
85% vs. 40%, p  0.0027). Patients treated with revascu-
arization had less angina and were taking fewer medica-
ions. These trials suggest that older and more symptomatic
atients are more likely to have symptomatic and survival
enefits from revascularization.
The Bypass Angioplasty Revascularization Investigation
BARI) trial provides further argument for optimized med-
cal therapy, even in patients undergoing revascularization
57). They reported a five-year angiographic substudy of the
ARI trial. Recurrent angina at five years occurred in 42%
CI-treated patients and 51% of CABG-treated patients.
mportantly, two-thirds of these recurrences were related to
isease progression of nontreated arteries. This trial is a
imely reminder that intense risk factor modification is
equired regardless of the revascularization strategy chosen.
n even more potent argument for aggressive medical
herapy is provided by the Pravastatin or Atorvastatin
valuation and Infection Therapy (PROVE-IT) trial (58).
n this study, patients with ACS who were randomized to
igh-dose atorvastatin had a significantly lower incidence of 5dverse cardiovascular events at two-year follow-up (22.4%
s. 26.3%, p  0.005).
actors influencing clinical outcomes after elective
CI. HOSPITAL VOLUME AND ON-SITE SURGERY. In 2004,
wo important studies were published that addressed the
elationship between different PCI centers and clinical
utcomes (59,60). In the first study, Wennberg et al. (59)
xamined outcomes in Medicare patients treated with PCI
t institutions with and without on-site cardiac surgery.
atients undergoing PCI without on-site surgery were more
ikely to have primary/rescue PCI for AMI, but after
djustment for baseline differences, these patients were
ound to have a mortality similar to AMI patients treated at
ites with on-site surgery. In contrast, patients undergoing
onemergent PCI had a significantly higher mortality in
ospitals without on-site surgery (adjusted odds ratio [OR]
.38, 95% CI 1.14 to 1.67, p  0.001), particularly in
ospitals performing 50 Medicare PCI procedures per
ear. In the second study, Epstein et al. (60) reported that
CI-related mortality was significantly higher in low-
olume centers (200 cases/year) than medium- or high-
olume centers (OR 1.21, 95% CI 1.06 to 1.28).
MPACT OF RENAL DYSFUNCTION, DIABETES, AND ANEMIA.
ith dramatic advances in interventional technology, PCI
uccess rates are higher. Therefore, patient clinical factors
ave taken a dominant role in predicting adverse outcomes
fter PCI (61). Numerous studies published in 2004 dealt
ith diabetes, chronic kidney disease (CKD), and anemia.
The adverse consequences of radiographic contrast ne-
hropathy (RCN) are well known. Marenzi et al. (62)
escribed the magnitude of this problem in patients under-
oing primary PCI. They found that RCN occurred in 19%
f patients and was associated with 31% in-hospital mor-
ality. Using two large angioplasty data bases, Mehran et al.
63) and Bartholomew et al. (64) have developed models
hat predict RCN. Both groups found that the presence of
KD, diabetes, age 75 years, intra-aortic balloon pump
se, congestive heart failure, and total contrast volume
redicted RCN. These studies can be used to predict RCN
nd, in the future, can be used to design prophylactic
trategies in high-risk patients.
A second major comorbidity in the PCI patient is
iabetes mellitus. Norhammar et al. (65) described wors-
ned survival in diabetic patients treated with either early
nvasive or early conservative strategies in the Fast Revas-
ularization During Instability in Coronary Artery Disease
FRISC II) trial. The relative value of early invasive therapy
as greater in diabetic than nondiabetic patients. Even
hen adjusted for the extent of CAD, diabetes remained a
trong independent predictor of mortality (RR 5.43, 95%
I 2.09 to 14.12, p  0.001). Diabetes and CKD often
o-exist in PCI patients. Nikolsky et al. (66) found this
ombination is associated with an explosive increase in
ne-year mortality. Diabetic patients without CKD had a
% one-year mortality rate, whereas those with CKD had
1
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April 5, 2005:1117–34 Year in Interventional Cardiology6.5% mortality and those on dialysis had 44% mortality
p  0.001). Corpus et al. (67) suggested that close
ttention to glycemic control must occur in PCI patients
ith diabetes. These authors followed 175 patients with
iabetes and found that target vessel revascularization
TVR) occurred in 34% of patients with glycosylated he-
oglobin (HbA1c) 7% versus 15% for those with HbA1c
7% (p  0.02). Because obesity and adult-onset diabetes
o-exist, it is intuitive that obese patients may have wors-
ned outcomes after PCI. It is therefore surprising that
hen Minutella et al. (68) queried the New York State
ngioplasty Registry, they found that mild to moderate
besity (body mass index [BMI] 30 to 39 kg/m2) had a mild
rotective effect. Only cases of extreme obesity (BMI 40
g/m2) had an increased risk of death.
Like obesity and diabetes, preprocedural anemia and the
eed for blood transfusions co-exist. Again, it seems intui-
ive that patients with severe coronary disease would benefit
rom optimizing the oxygen-carrying capacity of blood by
ormalizing the hematocrit. Lee et al. (69) found a striking
ncrease in postoperative creatine kinase-MB fraction (CK-
B) and troponin release, as well as one-year mortality, for
nemic PCI patients (hemoglobin [Hg] 10). Clinical
utcome was also worse for patients with mild anemia (Hg
0 to 12). Similarly, McKechnie et al. (70) found a higher
n-hospital mortality for PCI patients with anemia, regard-
ess of gender. The risk of preoperative anemia appears
agnified in the AMI population. Nikolsky et al. (17)
ound a strikingly higher in-hospital mortality (4.6% vs.
.1%, p  0.001), a higher risk of stroke (0.8% vs. 0.1%, p
0.005), and higher one-year mortality (9.4% vs. 3.5%, p
0.0001) for patients treated in the CADILLAC trial who
ad baseline anemia. These alarming data have led some to
uggest that preprocedural transfusions may be indicated
69). In this regard, the report of Rao et al. (71) is sobering.
hese authors describe an association of blood transfusions
ith increased mortality in three large trials of ACS, which
nrolled 24,112 patients, 10% of whom underwent blood
ransfusions. Unadjusted 30-day mortality was higher for
ransfused patients (8% vs. 3.08%, p  0.0001). A hazard
atio of 3.94 (95% CI 3.26 to 4.75) existed after adjustment
or baseline variables.
In summary, close attention to patient comorbidities is
ssential to minimize the risk of PCI. The presence of
KD, diabetes, severe obesity, and baseline anemia identi-
es individuals with greatly enhanced procedural risk and
orsened one-year survival. We hope that 2005 will provide
urther studies that shed light on new RCN preventative
trategies, a systematic approach to glycemic control and
nswers to the pressing question of whether blood transfu-
ions are necessary or harmful to anemic PCI patients.
herapeutic angiogenesis. Studies utilizing gene therapy
modifying a disease by introducing the deoxyribonucleic
cid [DNA] or ribonucleic acid [RNA] of a specific gene
nto cells) have reported disappointing results. Despite
romising initial data from the Angiogenic Gene Therapy dAGENT)-1 and -2 studies utilizing adenovirus-mediated
broblast growth factor-4 to induce angiogenesis, the larger
ivotal AGENT-3 study was stopped early. Although there
ere no safety concerns, the Data and Safety Monitoring
oard recommended that the trial be terminated due to
utility. Preliminary data were reported on 360 patients with
hronic angina randomized to receive intracoronary low-
ose adenovirus 5 fibroblast growth factor-4 (Ad5FGF-4),
igh-dose Ad5FGF-4, or placebo (72). All three groups
ad improvement in exercise duration at 12 weeks; however,
here were no differences between treatment arms. Interest-
ngly, sicker patients (55 years of age with CCS angina
lass III to IV or a baseline exercise duration of 300 s)
ere noted to have a greater exercise time with gene
herapy, suggesting some therapeutic benefit. Therefore,
ene therapy for angiogenesis appears to show subtle im-
rovements in symptoms, but objective measures of isch-
mia have not been convincing. Larger trials are clearly
eeded, perhaps with larger doses or different mode of
dministration. Moreover, because angiogenesis involves
ultiple growth factors, a combination of growth factors
nd/or cell therapy may be necessary. In this regard, a report
f 11 patients who received endocardial injection of autol-
gous bone marrow cells, compared with nine patients
eceiving usual care, demonstrated improvement in myocar-
ial perfusion and exercise capacity (73). However, because
his study was not randomized or blinded, investigator or
atient bias may have influenced the results.
HERAPIES FOR THE PREVENTION OF RESTENOSIS
ES. The year 2004 continued to provide trial data dem-
nstrating the superiority of DES over bare-metal stents in
imiting restenosis. We have summarized the currently
vailable data on the impact of different DES types on target
esion revascularization (TLR) in Figure 1. We have in-
luded all major randomized trials, as well as large registries
hat employed repeat angiography on a prospective, system-
tic basis. Because the main value of DES is to decrease
brointimal hyperplasia, the efficacy of various stents can be
etermined by the amount of angiographic late loss that
ccurs. Fortunately, most of these trials included short,
imple lesions in medium to large arteries. It is apparent that
oth sirolimus- and paclitaxel-eluting stents significantly
ecrease late loss and lessen the risk of TLR compared with
ontrols. Although sirolimus appears to be more potent
han paclitaxel in limiting late loss, TLR appears equally
ow. A threshold of late loss of 0.5 to 0.6 mm appears to
xist. Above this value there is no advantage over bare-metal
tents. Numerous prospective, comparative trials are being
onducted and will be reported in 2005. These trials will
ontinue to shed light on whether different stent types or
rug platforms will perform better. Until then, cost, avail-
bility, and deliverability of stents will drive usage patterns.
ONAPPROVED DES. The majority of the data on DES is
erived from trials using sirolimus and paclitaxel; however,
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Year in Interventional Cardiology April 5, 2005:1117–34tudies investigating different drugs, doses, and polymers are
ow available (74–80).
The First Use to Underscore Restenosis Reduction with
verolimus (FUTURE-1) trial randomized 42 patients to
eceive the everolimus-coated stent (n 27) versus bare-metal
tent (n 15) (74). Late loss was 0.11 mm; the restenosis rate
as 0% with everolimus; and intravascular ultrasound (IVUS)
onfirmed a significant reduction in neointimal volume (2.9 vs.
2.4 mm3/mm, p  0.001). The European Evaluation of
aclitaxel-Eluting Stent (ELUTES) pilot trial randomized
90 patients to receive a bare-metal stent versus one of four
ifferent doses of paclitaxel applied directly to the stent inter-
ace (nonpolymer-based) (75). Only the highest dose (2.7
g/mm2) appeared to be effective at reducing late loss (0.11 vs.
.73 mm, p  0.002) and restenosis (3.2% vs. 20.6%, p 
.056). Conversely, the DELIVER trial randomized 1,043
atients to receive a nonpolymer paclitaxel versus bare-metal
tent and found only a trend for reduction in target vessel
ailure (11.9% vs. 14.5%, p  0.12) (76). Moreover, in an
ngiographic subset, reductions in late loss (0.81 vs. 0.98 mm,
 0.003) and restenosis (14.9% vs. 20.6%, p  0.076) were
ess than expected with paclitaxel, compared with bare-metal
tents. High-dose dexamethasone loaded on a BiodivYsio
hosphorylchlorine-coated stent was found to be of no benefit
77). A pilot study showed that the 17-beta-estradiol-eluting
iodivYsio was safe and associated with a low restenosis rate
78).
Stents coated with the antiproliferative drug actinomycin
appeared to elicit a greater proliferative response. The
igure 1. Relationship between late loss and target lesion revascularization
TLR) in clinical trials evaluating bare-metal stent and drug-eluting stent
DES) platforms. Squares  sirolimus/everolimus DES; diamonds 
aclitaxel DES system; circles  bare-metal stent. Target lesion revascu-
arization is at nine months unless indicated (*TLR at six months; †TLR
t 12 months). Drug-eluting stents: 1  FUTURE-I*; 2  C-SIRIUS;
 SIRIUS; 4  E-SIRIUS; 5  TAXUS-IV; 6  TAXUS-II
slow-release group)†; 7  TAXUS-II (moderate-release group)†; 8 
AXUS-VI; 9  DELIVER. Bare-metal stents: 10  TAXUS-IV; 11 
ENESTENT (stent group); 12  STRESS (stent group); 13 
AXUS-II (moderate-release group)†; 14  TAXUS-II (slow-release
roup)†; 15  FUTURE-I; 16  DELIVER; 17  SIRIUS; 18 
-SIRIUS; 19 TXUS-VI; 20  E-SIRIUS.ctinomycin Eluting Stent Improves Outcomes by Reduc- ang Neointimal Hyperplasia (ACTION) trial randomized
60 patients to bare-metal, low-dose, or high-dose actino-
ycin D-coated stents (79). Late loss was higher in both
ctinomycin D groups, resulting in higher rates of TVR and
ACE at one year (34.8% and 43.1%) compared with the
are-metal stent (13.5%). Actinomycin D had no effect on
eath or MI. Conversely, the Study to Compare Restenosis
ate (SCORE) trial, which utilized acrylate polymer sleeves
ontaining 7-hexanoyltaxol (paclitaxel derivative), was
topped early (80). Despite reducing restenosis (7.4% vs.
2.7%, p  0.0001), stent thrombosis occurred in 10.3% of
atients receiving the hexanoyltaxol stent and resulted in a
ignificant increase in MI and cardiac death.
These studies indicate clear differences between DES,
ith some inducing harm. Further refinements of the
orrect drug, dose, and polymer will be necessary.
OOD AND DRUG ADMINISTRATION (FDA)-APPROVED
ES. The TAXUS-IV study randomized 1,314 patients
ndergoing single-vessel de novo PCI to receive a polymer-
ased paclitaxel stent versus a bare-metal stent (81). Mean
esion length was 13.4 mm, and 1.08 stents were implanted
er patient. Ischemia-driven TVR at nine months was
educed in the paclitaxel stent arm (4.7% vs. 12.0%, p 
.001). Cardiac death or MI at nine months was similar
etween the two groups. An additional three months of
ollow-up confirmed preservation of efficacy (82). One-year
ollow-up of the SIRIUS trial, in which 1,058 patients were
andomized to a sirolimus-eluting versus bare-metal stent,
emonstrated continued benefit (83). Target lesion revas-
ularization was 4.9% versus 20% (p  0.001), and there
as no difference in death or MI. In high-risk subsets (long
esions, small vessels, diabetes), a 70% to 80% reduction in
LR was observed. Furthermore, subsets that traditionally
ave the greatest benefit from bypass surgery did well with
mplantation of a Cypher stent. In fact, TLR was reduced
rom 22.3% to 6.9% (p  0.001) in diabetics (84), and
estenosis after stenting of the left anterior descending
oronary artery was reduced from 41.6% to 2% (p  0.001)
85).
EW LESION SUBSETS. The pivotal trials required for FDA
pproval of DES generally enrolled low-risk lesions. There-
ore, “real-world” registries and additional randomized trials
re needed. The Rapamycin-Eluting Stent Evaluated At
otterdam Cardiology Hospital Registry (RESEARCH)
reated 508 consecutive patients with Cypher DES and
ompared them with 450 consecutive patients who received
are-metal stents (86). Although the group treated with
ypher had more complex lesions (more type C lesions,
ifurcation, multivessel) and received more stents, one-year
ACE was reduced (9.7% vs. 14.8%, p 0.008), as well as
VR (3.7% vs. 10.9%, p  0.001).
Virtually all lesion subsets appear to benefit from DES. The
ESEARCH registry treated 102 very long lesions with
ypher stents (mean length 61.2 mm [range 41 to 134 mm])nd demonstrated low MACE, restenosis of 11.9%, and late
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April 5, 2005:1117–34 Year in Interventional Cardiologyoss of 0.13 mm (87). At the Transcatheter Cardiovascular
herapeutics meeting in 2004, Park (88) reported a study in
hich 739 long (24 mm) lesions were treated based on
perator preference to receive a Cypher stent (n 344), Taxus
tent (Boston Scientific, Maple Grove, Minnesota) (n 194),
r bare-metal stent. As expected, in-segment restenosis was
reatest in the bare-metal stent group (42.5%). Surprisingly,
espite a smaller baseline reference vessel size (which should
ncrease restenosis rates), the Cypher-treated lesions had a
ignificant reduction in restenosis compared with Taxus-
reated lesions (7.4% vs. 21.3%, p  0.001). Finally, the
anadian Sirolimus-Eluting Stent in Coronary Lesions (C-
IRIUS) trial showed a marked reduction in restenosis in long
esions treated with the Cypher stent compared with the
are-metal stent (89).
Two registries using DES for chronic total occlusion
CTO) have been reported. Hoye et al. (90) reported the use
f Cypher stents in 56 CTOs (one month duration) that
ere 2.35 mm in diameter, using 45.2 mm of the stent.
vent-free survival at one-year was 96.4%, and restenosis
ccurred in 9.1%. Werner et al. (91) reported 48 patients
ith total occlusion 2 weeks’ duration, who were treated
ith a Taxus stent (mean 40 mm) in vessels 2.57 mm in
iameter. Event-free survival was 87.5%, and restenosis
ccurred in 8.3%.
Additional lesion subsets that have shown good clinical
utcomes and low restenosis rates in Cypher registries and
andomized trials include saphenous vein grafts (92), AMI
93), aorto-ostial lesions (94), multivessel disease (95),
nprotected left main lesions (96,97), small vessels (98), and
tenting of the parent vessel of a bifurcation lesion (99).
owever, similar to bare-metal stent studies, stenting the
ide branch of the bifurcation appears to be associated with
igher subacute thrombosis and a nonsignificant increase in
ranch vessel restenosis. Finally, the Drug-Eluting Stents
or In-Stent Restenosis (ISAR-DESIRE) randomized trial
howed lower rates of restenosis were observed with Cypher
ompared with Taxus (14% vs. 22%), both of which were
uperior to PTCA (45%, p  0.001) when used to treat
n-stent restenosis (100).
REDICTORS AND TREATMENT OF DES RESTENOSIS. Rest-
nosis is an uncommon problem after implantation of DES
nd is generally focal rather than diffuse in nature. In 2004,
emos et al. (101) reported on predictors of restenosis after
irolimus-eluting stent implantation. Angiographic resteno-
is was found to be predominantly associated with lesion-
ased characteristics, including aorto-ostial location, treat-
ent of restenosis, long lesions, small vessels, as well as
iabetes. The optimal treatment strategy for patients with
estenosis in DES is not well defined. Data from the
ESEARCH registry suggest that implantation of a second
ES is safe and may be associated with a lower recurrence
ate than treatment with a bare-metal stent or balloon
ilation alone (102). Further investigation is required in this
rea. rTENT THROMBOSIS WITH DES. The year 2004 also
rought forth reports of stent thrombosis in DES, initially
aising widespread concern about the magnitude of this
roblem. These concerns were alleviated with data from
everal series that showed the incidence of stent thrombosis
ith sirolimus-eluting stents to be similar to the incidence
f thrombosis with bare-metal stenting (103,104). How-
ver, in another report, McFadden et al. (105) presented
our cases of late, angiographically confirmed thrombotic
cclusion approximately one year after implantation of
irolimus- or paclitaxel-eluting stents. All four cases arose
oon after aspirin or clopidogrel was interrupted, thus
ighlighting the importance of prolonged antiplatelet ther-
py in these patients.
ther devices for restenosis. CUTTING BALLOON. Based
n promising data from retrospective studies, the cutting
alloon has frequently been employed to treat in-stent
estenosis. The RESCUT trial prospectively evaluated the
fficacy of this device compared with conventional balloon
ilation in 428 patients with focal and diffuse in-stent
estenosis (106). The investigators observed less slippage
ith the cutting balloon, with a trend toward a lower rate of
dditional stenting in the cutting balloon group; however,
here was no difference in angiographic restenosis (primary
nd point) at seven months (cutting balloon 29.8% vs.
TCA 31.4%, p  0.82) or clinical events.
RACHYTHERAPY. Two trials of intracoronary brachyther-
py for the treatment of de novo lesions brought mixed
esults (107,108). These studies were designed to study the
ffect of beta-radiation after stenting to prevent restenosis.
oth trials demonstrated a significant reduction in in-stent
eointimal proliferation with beta-radiation (assessed by
ngiographic late loss in the Beta-Radiation Investigation
ith Direct Stenting and Galileo in Europe (BRIDGE)
rial; neointimal volume by IVUS in the Sabate et al. [108]
tudy). However, this benefit was offset by an edge effect in
he vessels treated with beta-radiation. Although neither
rial was powered to detect a difference in clinical events, the
nvestigators in both studies also observed a higher rate of
ate stent thrombosis in patients treated with brachytherapy
ompared with the control groups.
djunctive drug therapy to limit restenosis. Although
ES have greatly reduced restenosis, there are situations
here DES may be cost prohibitive (multiple lesions) or
essels may be too small or tortuous to accommodate a
ES. Therefore, oral medications to reduce restenosis may
e of benefit.
The VESPA trial randomized 700 patients with success-
ul PCI (83% of whom received stents) to verapamil 240 mg
wice a day versus placebo (109). A significant reduction in
VR was noted (19.3% vs. 29.3%, p  0.002). However,
his may have been due to the anti-anginal effects of
erapamil, as there was no difference in minimal lumen
iameter or percent stenosis, and only a trend toward a
eduction in restenosis (25.7% vs. 32.3%, p  0.06).
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Year in Interventional Cardiology April 5, 2005:1117–34Sirolimus-coated stents have nearly eliminated restenosis,
nd systemic oral sirolimus has prevented intimal hyperpla-
ia in animal models. Two small trials have evaluated this
lass of oral drugs in patients treated with bare-metal stents
110,111). The Oral Sirolimus to Inhibit Recurrent In-
tent Stenosis (OSIRIS) trial randomized 300 patients with
n-stent restenosis to placebo, usual-dose or high-dose
irolimus for 10 days, starting two days before PCI (110).
ignificant reductions in angiographic restenosis were seen
n the high-dose sirolimus group compared with placebo
22.1% vs. 42.2%). Low-dose sirolimus had little effect.
nother trial gave open-label rapamycin 2 mg (n  30)
ersus 5 mg (n  30) for 30 days (111). The 5-mg dose had
ore side effects, and 30% of patients did not complete the
ourse. Late loss (0.6 mm) and restenosis rates (7%) were
ow in both groups, suggesting a possible benefit.
Although earlier small trials using folic acid suggested a
eduction in restenosis, Lange et al. (112) reported a
egative trial of 636 patients randomized to folic acid, with
6 and B12 versus placebo. In fact, folate and B-complex
itamins appeared to increase the risk of restenosis (34.5%
s. 26.5%, p 0.05) and TVR (15.8% vs. 10.6%, p 0.05).
THER CORONARY DEVICES
mbolic protection devices. The treatment of saphenous
ein graft disease remains a challenge in interventional
ardiology. The results of two clinical trials investigating
ew embolic protection devices were reported in 2004
Table 5) (113,114).
The Protection During Saphenous Vein Graft Interven-
ion to Prevent Distal Embolization (PRIDE) trial com-
ared the efficacy of the TriActiv distal balloon occlusion
ystem (Kensey Nash, Exton, Pennsylvania) with either the
uardWire or FilterWire EX (Boston Scientific) devices
113). After PCI, there was no significant difference in the
ncidence of final TIMI flow grade 3 between the study
roups (TriActiv 99.1% vs. control 97.8%, p 0.20). There
as a higher rate of transfusion in the TriActiv group (8.6%
able 5. Trials of Devices for Saphenous Vein Graft Intervention
Study Design n
mbolic protection device
CAPTIVE (114) PCI in SVG disease; randomized to
PCI with MedNova EmboShield
vs. GuardWire
84
PRIDE (113) PCI in SVG disease; randomized to
PCI with TriActiv System or
active control (GuardWire or
FilterWire)
89
overed stents
SYMBIOT III (115) PCI in SVG disease; randomized to
PCI with Symbiot stent vs. bare-
metal stent
40ACE  major adverse cardiac events; PCI  percutaneous coronary intervention; SVGs. 4.1%, p  0.02), related to use of larger 8-F catheters in
he early phase of the trial. At 30 days, the primary end
oint (MACE) was similar in the TriActiv and control
roups, thus suggesting that the TriActiv system provides a
imilar degree of embolic protection to the currently ap-
roved devices.
In contrast, the Prospective, Randomized, Controlled
rial of Distal Protection With the Third Generation
edNova EmboShield Compared to the GuardWire or
ilterWire (CAPTIVE) trial brought somewhat mixed
esults (114). The CAPTIVE trial evaluated the efficacy of
he MedNova EmboShield filter (MedNova-Abbott, Gal-
ay, Ireland) compared with the Medtronic GuardWire. At
0 days, the incidence of MACE in the noninferiority
ohort was 11.4% in the EmboShield group and 9.1% in the
uardWire group (p  0.057). A modified intent-to-treat
nalysis was also performed, excluding patients in whom the
andomization strategy was not attempted or patients
reated without protection. In this analysis, the EmboShield
as found to be noninferior to the GuardWire (10.1% vs.
.8%, p  0.022).
overed stents. An alternative approach to treatment of
aphenous vein graft disease has been the use of membrane-
overed stents. It was proposed that the polytetra fluoroeth-
lene (PTFE) membrane would reduce distal embolization
nd also reduce neointimal proliferation through the stent
truts. The Prospective, Randomized Trial of a Self-
xpanding PTFE Stent Graft During SVG Intervention
SYMBIOT-III) compared the Symbiot self-expanding
TFE-covered nitinol stent (Boston Scientific, Minneapo-
is, Minnesota) with bare-metal stents in saphenous vein
raft intervention (115). Patients who received the Symbiot
tent had a slightly higher incidence of MACE (30.6% vs.
6.5%, p 0.43), and there was no difference in the primary
nd point (diameter stenosis by angiography at eight
onths) between the study groups. These data suggest that
se of the Symbiot stent does not confer any additional
Primary End Point Results
MACE at 30 days MACE 11.4% vs. 9.1% (p  0.057 for
noninferiority). In a modified ITT
analysis (excluding patients not
treated with protection), the
CardioShield was noninferior to GW
(10.1% vs. 8.8%, p  0.022)
MACE at 30 days In the noninferiority arm, PCI with the
TriActiv system resulted in a similar
incidence of MACE to the active
control group (11.2% vs 10.1%)
Percent diameter stenosis at
8 months
No reduction in restenosis with the
Symbiot stent9
4
0 saphenous vein graft.
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esions.
AROTID ARTERY AND AORTIC DISEASE
iven the enormous controversy and bitter turf battles
aging about noncoronary percutaneous endoluminal repair,
he year 2004 finally provided scientific data. Clinicians can
ow begin to make rationale decisions about the choice of
urgical or percutaneous repair for carotid lesions and
bdominal aneurysm.
The Stenting and Angioplasty with Protection in Patients at
igh Risk for Endarterectomy (SAPPHIRE) trial is the first
rial of carotid stenting with distal protection versus surgical
ndarterectomy (116). In this trial, 334 patients with carotid
esions and major co-morbidities (severe pulmonary disease,
ongestive heart failure, 80 years of age) were enrolled. The
rimary end point—MACE at one year—was lower in the
tent group (12.2% vs. 20.1%, p  0.053). This was largely
riven by a lower risk of MI in the stent group (2.5% vs. 8.1%,
 0.03). On the basis of this trial and the Guidant
orporation-sponsored ARCHER registry (117), both the
DA and Centers for Medicare and Medicaid Services have
pproved carotid stenting. Promising outcome data were also
eported from registries evaluating newer generation carotid
tents and embolic protection devices (118,119). Major chal-
enges persist in this field, including training and credentialing
ssues, turf issues, and a lack of prospective data concerning
ower risk patients who are currently being treated surgically.
The other major field—endoluminal stent grafting for
bdominal aortic aneurysms—had important trial data pub-
ished in 2004. Prinssen et al. (120) randomized 345
atients with aneurysms 5 cm in diameter, who were
ligible for surgical or stent graft repair. Perioperative
ortality (4.6% vs. 1.2%, p  0.10) and 30-day MACE
ended to be lower in the stent graft group. Although this
rial is the first to scientifically compare these techniques, an
rgument can be made that a 30-day end point does not deal
ith the major limitation of stent grafting (late endoluminal
eak). Until a trial shows mortality reduction, controversy
ill still exist about surgical or stent graft repair.
A final trial involving peripheral vascular disease patients
erformed in 2004 that needs mention is the Coronary
rtery Revascularization Prophylaxis (CARP) trial (121).
o determine the value of preoperative revascularization,
10 patients scheduled to undergo noncardiac vascular
urgery who had stable symptoms, preserved left ventricular
unction, and anatomy suitable for CABG or PCI were
andomized to a strategy of preoperative coronary revascu-
arization or medical therapy. At 2.7-year follow-up, no
ifference in mortality or postoperative MI existed. Al-
hough only 9% of all patients were randomized, this trial
hould change the practice of cardiology concerning preop-
rative assessment and preoperative revascularization in
table peripheral vascular disease patients who require non-
ardiac surgery.DJUNCTIVE PHARMACOTHERAPY
ntiplatelet therapy. The Intracoronary Stenting and An-
ithrombotic Regimen (ISAR) investigators continue to
edefine antiplatelet regimens. The Intracoronary Stenting
nd Antithrombotic Regimen Rapid Early Action for Cor-
nary Treatment (ISAR-REACT) trial enrolled 2,159 pa-
ients who were pretreated with 600 mg of clopidogrel
2 h before elective PCI (122). Patients with recent AMI,
nstable angina (with positive troponin, or electrocardio-
raphic changes), or angiographic evidence of thrombus
ere excluded. Patients were randomized to abciximab with
ow-dose heparin (70 /kg) versus placebo with high-dose
eparin (140 /kg). The abciximab group had more pro-
ound thrombocytopenia (1% vs. 0%, p  0.002) and
ransfusions (2% vs. 1%, p 0.007). The primary end point
f combined death, MI, or urgent TVR at 30 days was
dentical between the two groups, as was the rate of TVR,
I, large MI, or any combinations of ischemic end points.
he Intracoronary Stenting and Antithrombotic Regimen-Is
bciximab a Superior Way to Eliminate Elevated Thrombotic
isk in Diabetics (ISAR-SWEET) study was designed to
pecifically address whether the benefit of clopidogrel could be
xtended to diabetic patients. The trial randomized 701 dia-
etic patients undergoing PCI who were pretreated with 600
g clopidogrel to receive abciximab versus placebo (123). The
ajority of patients (80%) were treated with bare-metal stents
10% received DES and 10% PTCA). The primary end point
f death or MI at one year was similar between the abciximab
nd placebo groups (8.3% vs. 8.6%, p  0.91). Interestingly,
ngiographic restenosis was significantly reduced in the abcix-
mab group (28.9% vs. 37.8%, p  0.01). Therefore, the two
SAR trials suggest that glycoprotein IIb/IIIa receptor inhib-
tors may be safely withheld in elective patients if they are
retreated with 600 mg clopidogrel (given a mean of 6 h before
CI) and high-dose heparin.
There has been growing interest in resistance to anti-
latelet therapy, which appears to occur more frequently
han expected. Chen et al. (124) used a rapid platelet
unction assay to determine aspirin responsiveness in 151
atients pretreated with 300 mg clopidogrel 12 h before
lective PCI. They found that 19.2% of patients were
spirin resistant, and these patients had a higher incidence
f any CK-MB elevation after PCI (51% vs. 24.6%, p 
.006). Likewise, Matetzky et al. (125) performed platelet
ggregation studies in 60 AMI patients undergoing primary
CI with stenting. Patients were divided into four quartiles
ased on adenosine diphosphate-induced platelet aggrega-
ion at day 6 (103%, 69%, 58%, and 33% of baseline).
atients in the first resistant quartile had 40% recurrent
ardiac event at six months, compared with 6.7%, 0%, and
% in the second, third, and fourth quartiles (p  0.007).
lthough these data are intriguing, larger studies are needed
o confirm these results and to determine appropriate
anagement strategies.
Meta-analyses have suggested that abciximab may offer a
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Year in Interventional Cardiology April 5, 2005:1117–34urvival advantage in STEMI patients (126). Because ur-
ent revascularization occurs frequently in patients with
CS or STEMI, re-administration of the monoclonal
ntibody, abciximab, has the potential for antigenicity. In a
egistry of 1,342 patients undergoing PCI who received
bciximab two or more times, there were no reported cases
f anaphylaxis (127). Procedural success occurred in 98%,
nd only 2.3% of patients had significant bleeding, results
imilar to first-time administration. However, profound
hrombocytopenia (20,000) occurred in 2%, and patients
etreated within one month of previous abciximab were
articularly at risk (12.2%).
ntithrombin therapy. On the basis of the REPLACE-2
rial, bivalirudin has become a widely accepted alternative to
nfractionated heparin for patients undergoing PCI. Long-
erm clinical outcome data from the Randomized Evalua-
ion of PCI Linking Angiomax to Reduced Clinical Events
REPLACE-2) trial were reported in 2004 (128). At six
onths and one year, the incidence of death and MI was
imilar in both study groups, suggesting that the efficacy of
ivalirudin remains comparable to that of heparin plus
lycoprotein IIb/IIIa inhibition at late follow-up.
gents to prevent RCN. Apart from preprocedural hydra-
ion, measures to prevent RCN have proven disappointing.
n this regard, the report from Merten et al. (129) provides
ope that sodium bicarbonate administration may be of
alue to prevent this complication. These authors random-
zed 119 patients with mild chronic kidney disease (creati-
ine1.1 mg/dl) to sodium chloride or sodium bicarbonate
dministrated during procedures, where on average of 370
l of iopomidol was used. They found that RCN developed
n 1.7% of sodium bicarbonate-treated and 13.6% of sodium
hloride-treated patients. A follow-up registry of 191 sim-
lar patients treated with sodium bicarbonate yielded RCN
n 1.6% of patients. In another study, Spargias et al. (130)
ound that prophylactic oral ascorbic acid may also protect
gainst RCN in high-risk patients. Although these studies
rovide important steps forward, RCN remains a challeng-
ng and difficult problem in clinical practice and will be an
able 6. Top Ten “Must-Read” Published Studies in Interventio
Acronym
OOST (30) Intracoronary autologous bone marrow cell
RAVE (8) Early administration of reteplase plus abcix
for percutaneous coronary intervention: a
ARP (121) Coronary artery revascularization before ele
SAR-REACT (122) A clinical trial of abciximab in elective perc
SAR-SWEET (123) Randomized clinical trial of abciximab in d
treatment with a high loading dose of cl
erten et al. (129) Prevention of contrast-induced nephropath
EPLACE-2 (128) Long-term efficacy of bivalirudin and provi
IIb/IIIa blockade during percutaneous co
APPHIRE (116) Protected carotid artery stenting versus end
YNERGY (49) A prospective, randomized trial of enoxapa
elevation acute coronary syndromes man
AXUS-IV (81) A polymer-based, paclitaxel-eluting stent inmportant area for ongoing investigation in 2005.ONCLUSIONS
e have provided a list of what we consider to be the 10 most
nfluential original articles published in 2004 (Table 6). Al-
hough such lists are subjective, we believe that these trials
ill stand the test of time with respect to their impact on the
eld. The SYNERGY and REPLACE trials further ad-
ance the science of periprocedural antithrombotic therapy.
he ISAR trials further advance the science of periproce-
ural antiplatelet therapy. The BRAVE trial is the first in a
eries of trials of facilitated angioplasty and may foreshadow
he results of large reperfusion trials. The SAPPHIRE and
ARP trials begin scientific evaluation by the cardiology
ommunity of issues related to noncoronary vascular disease.
he TAXUS-IV trial is the seminal study of the drug
lution of paclitaxel. The Merten study provides a new,
asily used method of prophylaxis for contrast nephropathy.
inally, the BOOST trial opens the field of regenerative
edicine for repair of myocardial damage. We believe that
ach of these trials require detailed study and analysis by
tudents of the field. We look forward to an equally
aunting task of collating and summarizing the trials of
005.
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